Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-12
2005-07-12
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S436000, C514S445000, C514S509000, C514S645000
Reexamination Certificate
active
06916835
ABSTRACT:
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic compound comprising a nitrate ester, or a pharmaceutically acceptable salt or ester thereof.
REFERENCES:
patent: 4780560 (1988-10-01), Kumonaka et al.
patent: 4801596 (1989-01-01), Simon et al.
patent: 4863949 (1989-09-01), Simon et al.
patent: 5049694 (1991-09-01), Bron et al.
patent: 5234956 (1993-08-01), Lipton
patent: 5284872 (1994-02-01), Sandrock et al.
patent: 5428061 (1995-06-01), Sandrock et al.
patent: 5455279 (1995-10-01), Lipton
patent: 5621000 (1997-04-01), Arena et al.
patent: 5700947 (1997-12-01), Soldato
patent: 5780495 (1998-07-01), Del Soldato
patent: 5861426 (1999-01-01), Del Soldato et al.
patent: 6127370 (2000-10-01), Smith et al.
patent: 6140309 (2000-10-01), Thomas et al.
patent: 6310052 (2001-10-01), Thatcher et al.
patent: 6365579 (2002-04-01), Thatcher et al.
patent: 6433019 (2002-08-01), Nawa
patent: 6436996 (2002-08-01), Vitek et al.
patent: 764461 (1967-08-01), None
patent: 792246 (1968-08-01), None
patent: 2158368 (1994-09-01), None
patent: 0882716 (1998-12-01), None
patent: 51-125750 (1976-11-01), None
patent: 01-304353 (1989-12-01), None
patent: 7-26949 (1995-03-01), None
patent: PCT/EP91/00290 (1991-02-01), None
patent: PCT/US93/09019 (1993-09-01), None
patent: WO 95/00477 (1995-01-01), None
patent: WO 98/42661 (1998-10-01), None
patent: WO 98/43621 (1998-10-01), None
patent: WO 99/37616 (1999-07-01), None
patent: WO 00/31060 (2000-06-01), None
patent: WO 00/54773 (2000-09-01), None
patent: WO 00/76318 (2000-12-01), None
Harrison's Principles of Internal Medicine, Isselbacher et al. eds., 13thed., vol. 2, published 2000 by McGraw-Hill, Inc., pp. 2269 2280.
Lockhart et al., Experimental gerontology, (Jan.-Feb. 2003) 38 (1-2) 119-28 (Medline Abstract AN#2003036411.
Abe, K., C. Takeyama, K. Yoshimura, “Effects of S-8510, a novel benzodiazephine receptor partial inverse agonist, on basal forebrain lesioning-induced dysfunction in rats.”Eur. J. Pharmacol. 347(1998) 145-152.
Arancio, O., E.R. Kandel, R.D. Hawkins, “Activity-dependent long-term enhancement of transmitter release by presynaptic 3′,5′-cyclic GMP in cultured hippocampal neurons.” Nature 376 (1995) 74-80.
Bernabeu, R., P. Schmitz, M.P. Faillace, I. Izquiredo, J.H. Medina, “Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning.” NeuroReport 7 (1996) 585-586.
Bernabeu, R., N. Schroder, J. Quevedo, M. Cammarota, I. Izquiredo, J.H. Medina, “Further evidence for the involvement of a hippocampal cDMAP/cGMP-dependent protein kinase cascade in memory consolidation,” NeuroReport 8 (1997) 2221-2224.
Pallarés, M., M. Damaudéry; J. Day, M. Le Moal, and W. Mayo, “The neurosteroid pregnenolone sulfate infused into the nucleus basalis increases both acetylcholine release in the frontal cortex or amygdala and spatial memory.” Neuroscience 87 (1998) 551-558.
Wu. J., Y. Wang, M.J. Rowan, and R. Anwyl, “Evidence for involvement of the cGMP-protein kinase G signaling system in the induction of long-term depression, but not long-term potentiation, in the dentate gyrus in vitro.” J. Neurosci. 18 (1998) 3589-3596.
Lipton, et al., “NO-related species can proect from focal cerebral ischemia/reperfusion”Pharmacol. Cereb. Ishemia,1996, 6thInt. Symp.; pp. 183-191.
Lipton et al., “S-nitrosylation of NMDA receptor and caspases affords neuroprotection from NMDA receptor-mediated insults”Pharmacol. Cereb. Ishemia,1999, Int. 7thSymp.; pp. 217-226.
Uchiyama-Tsuyuka, et al., “VA-045, a novel apovincaminic acid derivative attenuates neuronal injury induced by hypoxia or by excitatory amino acids in cultures of rat cortices”Life Sci.,1996, 59(18):1571-1578.
Ramos-Zuniga, et al., “Neuroprotection in selective focal ischemia in rats by nitrates, an alternative redox manipulation on nitric oxide: experimental Model”Minim. Invas. Neurosurg.,1998, 41(3):152-160.
Buisson, A., et al., “Deleterious and protective modulatory role of nitric oxide during focal cerebral ischaemia.”Journal of Cerebral Blood Flow and Metabolism,13:S166 (1993).
Lipton, S.A., et al., “Nitric oxide in the central nervous system.”Progress in Brain Research,103:359-364 (1994).
Manchester, K.S., et al., “Chronic administration of nitroglycerin decreases cerbral infarct size.”Abstract, Neurology43:A365 (1993).
Artz, J.D., K. Yang, J. Lock, C. Sanchez, B.M. Bennett, and G.R.J. Thatcher, “Reactivity of thionitrate esters: putative intermediates in nitrovasodilator activity.” Chem. Commun. (1996) 927-928.
Bak, A.W., W. McKnight, P. Li, P. Del Soldato, A. Calignano, G. Cirino, J.L. Wallace, “Cyclooxygenase-Independent Chemoprevention with an Aspirin Derivative in a Rat Model of Colonic Adenocarcinoma.” Life Sci. 62 (1998) 367-373.
Barger, S.W., R.R. Fiscus, P. Ruth, F. Hofmann, M.P. Mattson, “Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of β-amyloid precursor protein.”J. Neurochem. 64(1995) 2087-2096.
Bennett, B.M., B.J. McDonald, R. Nigam, and W.C. Simon, “Biotransformation of organic nitrates and vascular smooth muscle cell function.” Trends Pharmacol. Sci. 15 (1994) 245-249.
Bennett, B.M., B.J. McDonald, R. Nigam, P.G. Long, and W.C. Simon, “Inhibition of nitrovasodilator- and acetylcholine-induced relaxation and cyclic CMP accumulation by the cylochrome P-450 substrate, 7-ethoxyresorufin.” Can. J. Physiol. Pharmacol. 70 (1992) 1297-1303.
Berge, S.M., L.D. Bighley, and D.C. Monkhouse, “Pharmaceutical Salts.” J. Pharm. Sci. 66 (1997) 1-19.
Bloeman, P.G.M., P.A.J. Henricks, L. van Bloois, M.C. van den Tweel, A.C. Bloem, F.P. Nijkamp, D.J.A. Crommelin, and G. Storm, “Adhesion molecules: a new target for immunoliposome-mediated drug delivery.” FEBS Lett. 357 (1995) 140-144.
Briscoe, P., I. Caniggia, A. Graves, B. Benson, L. Huang, A.K. Tanswell, and B.A. Freeman, “Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes.” Am. J. Physiol. (1995) 374-380.
Bullock, R., A. Zauner, J.J. Woodward, J. Myseros, S.C. Choi, J.D. Ward, A. Marmarous, H.F. Young, “Factors affecting excitatory amino acid release following severe human head injury.” J. Neurosurg. 89 (1998) 507-518.
Cameron, D.R., A.M.P. Borrajo, B.M. Bennett, and G.R.J. Thatcher, “Organic nitrates, thionitrates, peroxynitrites, and nitric oxide: a molecular orbital study of RXNO, RXONO (X=O,S) rearrangement, a reaction of potential biological significance.” Can. J. Chem. 73 (1995) 1627-1638.
Chan, P.H., M. Kawase, K. Murakami, S.F. Chen, Y. Li, B. Calagui, L. Reola, E. Carson, and C.J. Epstein, “Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion.” J. Neurosci. 18 (1998) 8292-8299.
Chen, J., T. Nagayama, K. Jin, R.A. Stetler, R.L. Zhu, S.H. Graham, and R.P. Simon. “Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia.” J. Neurosci. 18 (1998) 4914-4928.
Chong, S., and H.-L. Fung, “Biochemical and pharmacological interactions between nitroglycerin and thiols. Effects of thiol structure on nitric oxide generation and tolerance reversal.” Biochem. Pharm. 42 (1991) 1433-1439.
Cohen, G.M., “Caspases: the executioners of apoptosis.” Biochem. J. 326 (1997) 1-16.
Du, Y., K.R. Bales, R.C. Dodel, E. Hamilton-Byrd, J.W. Horn, D.L. Czilli, L.K. Simmons, B. Ni, and S.M. Paul, “Activation of a caspase-3-related cysteine protease is required for glutamate-mediated apoptosis of cultur
Bennett Brian M.
Boegman Roland J.
Jhamandas Khem
Reynolds James N.
Thatcher Gregory R. J.
Clark & Elbing LLP
Henley III Raymond J.
Queen's Uninversity at Kingston
LandOfFree
Nitrate esters and their use for neurological conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrate esters and their use for neurological conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrate esters and their use for neurological conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403560